We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bespak | BPK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 667.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 667.00 | 667.00 |
| Top Posts |
|---|
Posted at 20/4/2007 08:08 by playtime99 Anyone care to comment on the recent price drop at BPK, is it solely due the reported slow take up of Exubera, or is the recently announced acquisition partly responsible ... are they overpaying?Thanks for any contributions. |
Posted at 19/1/2007 19:54 by tuning peg This has always been a solid if unexciting business with good management. The CFC inhaler market decline will hopefully be offset by non CFC inhaler sales plus Exubera (if we share the company's optimism). More interestingly in my view is the sea change in the company's ambitions e.g. doubling profits in five years and hinting strongly that they will achieve this through acquisitions rather than relying on organic growth. At least the management have put their necks on the line and we must salute them for this.My real concerns are that it has always been a cash rich company. With the acquisistion of King the war chest has gone and the company is now in debt. Further acquisitions will ramp up debt so the pressure is on to make some quality acquisitions. Additionally we need to be mindful that King has increased the company's dollar exposure and in the current £/$ rate environment this could be a drag on profitability. The flip side of course is that future $ acquisitions become much cheaper and I suspect that given Throdahl is American with prior experience of the US pharma / medical devices market he centre his focus in this area For what it is worth I am in pretty big on BPK and I am fully intending to hold and will look to buy more on any weakness but given the rises over the last 2 days it might be lucky if I get back in sub £7 at this rate. |
Posted at 19/1/2007 08:59 by tommy ten chins I quote "LONDON (AFX) - Bespak PLC unveiled a target to double pretax profits over the next five years after it unveiled first-half underlying profit growth of 39 pct, amid strong trading across all its businesses. In the 26 weeks to Oct 28, profit before tax and special items climbed to 8.5 mln stg from 6.1 mln in the same period last year. The maker of medical devices reiterated that it expects its full-year result to beat expectations. Revenues climbed 61 pct to 62.1 mln stg, reflecting in part the first full half-year contribution from King Systems, the US respiratory equipment maker bought last year, which added almost a third to sales and profits. The new business exceeded expectations in 2006, delivering underlying sales growth of 10 pct in this period, Bespak said. It also reported strong demand at its inhaled drug delivery arm, which makes valves and inhalers used to deliver respiratory drugs. Sales surged 22 pct at the division, amid record sales of its metered dose inhalation (MDI) valves and rapid growth of Exubera, the inhaled insulin drug made by Pfizer, for whom Bespak manufactures the device. The group is expecting strong trading to continue in MDI valves, Exubera inhaler production, and at King Systems this year. "Bespak has experienced strong growth in the first half year, and the board believes that the Company will have a full year that again exceeds its original expectations," chief executive Mark Throdahl said in a statement. "Bespak has set a target to double its profit before tax over the next five years, although the current profile of our businesses means that we may out-perform or under-perform this trajectory in any given year." The company sees growth coming from a strategy to grow both organically and by acquisitions. Throdahl has made no secret of his desire to expand in the anaesthesiology and respiratory products industry, which Bespak entered via the acquisition of King Systems, and the company has been assessing potential targets. The firm maintained its interim dividend at 7.0 pence. Bespak shares, which advanced 25 pct last year, closed Wednesday at 620 pence, valuing the company at 176 mln stg. amy.brown@afxnews.co End quote. These will now start to steadily climb IMHO and I am considering increasing my holding. any views? |
Posted at 11/9/2006 15:24 by tiltonboy c2i,I've taken profits on BPK, selling the last lot at 672p, just over a week ago. Whilst I think there might be more in it, I am happy with the % gain, in a relatively short space of time. There are a couple of cautionary comments in the statement, so better to bag the profit. tiltonboy |
Posted at 11/9/2006 15:08 by contrarian2investor I wonder if today's new rise in down to more institutions coming on board or is has BPK been tipped somewhere? Any news fellow holders?Thanking you in anticipation of your reply c21 |
Posted at 31/8/2006 16:36 by contrarian2investor tiltonboy,sorry that I didn't reply earlier. My reasons for my earlier speculation is thus: Bespak is the leader in the UK of inhaleable products, Glaxo have already made a massive investment in BPK's product line. They (Glaxo) need additional revenues, so what better way than taking this nice little cash cow in-house. If you look at recent purchases by Pharma companies they have mainly been bios. So BPK is in an interesting position. Today we have had another nice rise to a five year high and Barclays have been buying up their holdings again over the past 2 months. So BPK should breach £7 before 2007. Then the sales will really kick in during 2007 and others will start touting them, so watch this space. All in my humble opinion. DYOR. By the way Tiltonboy do happen to hold BPK shares? Your's with integrity, C2I |
Posted at 07/6/2006 17:33 by contrarian2investor Well I'm not going anywhere until Glaxo make a move. In light of the fact that the big pharma's appear to be buying the small/medium size biotech for future growth. Eventually BPK will be snapped up. In the meantime it has been a relatively safe port in the storm. c21 |
Posted at 19/4/2006 08:07 by felix99 Hmmm . NICE have rejected Exubera for the NHS last night. Wonder if it will have an effect on BPK . They make the inhalers and have a royalty deal with Pfizer. Must be a potnetial £100m sale down the swanny for a bit. They earn 15% royalty I beleive. Anyone know if that is on top of production costs or essentially an all inclusive price? |
Posted at 14/11/2005 07:32 by waldron Trading StatementRNS Number:0493U Bespak PLC 14 November 2005 For immediate release 14 November 2005 Bespak plc Trading update for the 26 weeks to 29 October 2005 Bespak plc (LSE: BPK), a leader in specialty medical devices, announces that trading in the first half was in line with its expectations. There has been replenishment of the CFC valve supply chain in the US following the FDA ruling on phase-out of CFC albuterol formulations, continuing growth in HFA valve sales and inventory building by customers of US-manufactured products in advance of closure of the Cary facility. Looking ahead, two key events will continue to influence Bespak's performance. Firstly, customers in the US are continuing to develop their marketing plans for the replacement of CFC with HFA in albuterol formulations by December 2008. Secondly, Bespak awaits the approval of Exubera(R). In September the FDA's clinical advisory panel recommended approval of Exubera(R) in the US, whilst in October the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommended approval of Exubera(R) in Europe. In the second half, we expect additional expenditure to strengthen the businesses, general inflationary cost pressures and reversal of inventory building by customers of previously US-manufactured products that have been transferred to the UK, which leads us to be cautious in the short term. However, we are increasingly confident in the prospects for growth from Exubera(R). Bespak will report its interim results on 18 January 2006. For further information, please contact: Bespak plc Tel: +44 (0) 1908 525 241 Mark Throdahl - Chief Executive Martin Hopcroft - Group Finance Director Buchanan Communications Tel: +44 (0) 20 7466 5000 Tim Thompson / Mark Court / Mary-Jane Johnson About Bespak plc Bespak, a specialty medical devices company, is at the forefront of developing new delivery systems for the pharmaceutical industry. The company has a product range covering metered dose inhalers, dry powder devices, actuators and compliance aids. The company also develops and manufactures drug delivery devices for leading global pharmaceutical companies. The group, which has facilities in King's Lynn and Milton Keynes in the UK, is a public company quoted on the Official List of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com. This information is provided by RNS The company news service from the London Stock Exchange END TSTZGMMMNMZGKZM |
Posted at 14/10/2005 12:07 by grupo guitarlumber Exubera UpdateRNS Number:6952S Bespak PLC 14 October 2005 For immediate release 14 October 2005 Bespak plc Welcomes Positive Opinion on Exubera(R) Bespak plc (LSE: BPK), a leader in specialty medical devices, is pleased to note that Pfizer Inc announced yesterday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluations Agency (EMEA) has issued a positive opinion recommending the approval of Exubera(R) inhaleable insulin for the treatment of type 1 and type 2 diabetes in adults. The proposed therapeutic indication for Exubera(R) is for the treatment of adult patients with type 2 diabetes not adequately controlled with oral antidiabetic agents and requiring insulin therapy; and for the treatment of adult patients with type 1 diabetes, in addition to long or intermediate acting subcutaneous insulin, for whom the potential benefits of adding inhaled insulin outweigh the potential safety concerns. Exubera(R), which is the product of a joint-development program between Pfizer and sanofi-aventis, is an inhaled rapidly acting insulin that is inhaled into the lungs prior to eating, using a proprietary inhalation device and powdered insulin formulation developed by Nektar Therapeutics. The product represents a major advance in insulin delivery and will be the first non-injectable form of insulin available since the discovery of the drug in the 1920s. Bespak, in conjunction with Nektar, has developed the production process and will manufacture the proprietary inhalation device for Exubera(R). Exubera(R) was filed with the US Food & Drug Administration (FDA) on 2nd March 2005, and an FDA advisory committee recommended the approval of Exubera(R) on 8th September for the treatment of adults with type 1 and 2 diabetes. Pfizer awaits the approval by the FDA in the US as well as approval by the European Commission. It is anticipated that once fully launched, Exubera(R) will be a significant source of revenue growth for Bespak's Device & Manufacturing Services division. Mark Throdahl, Bespak's Chief Executive, said: "We are delighted by this recommendation from the CHMP, which moves us closer to European regulatory approval of this important new treatment for diabetes." For further information please call: Bespak plc Mark Throdahl - Chief Executive +44 (0) 20 1908 552 600 Martin Hopcroft - Group Finance Director Buchanan Communications +44 (0) 20 7466 5000 Tim Thompson / Mark Court / Mary-Jane Johnson Notes for Editors: About Bespak plc Bespak, a specialty medical devices company, is at the forefront of developing new delivery systems for the pharmaceutical industry. The company has a product range covering metered dose inhalers, dry powder devices, actuators and compliance aids. The company also develops and manufactures drug delivery devices for leading global pharmaceutical companies. The group, which has facilities in King's Lynn and Milton Keynes in the UK, is a public company quoted on the Official list of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com. About diabetes It is estimated that nearly 180 million people worldwide suffer from diabetes, and the number is expected to rise to 300 million people in the next 20 years. Currently, diabetes and its complications account for more than $100 billion in healthcare costs annually in the United States. This information is provided by RNS The company news service from the London Stock Exchange END RESILFSFIRLSLIE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
